Clinical Trial Update: Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating BCD-178 in combination with Perjeta as neoadjuvant therapy for HER2-positive breast cancer is ongoing and not currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BCD-178
• Perjeta (pertuzumab)

Snippet

Sponsor: Biocad | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING